Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 9/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981601 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2HPGDMAPTALDH1A1PKM | |
| SCHEMBL19974119 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2HPGDMAPTALDH1A1PKM | |
| SCHEMBL19974118 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2HPGDMAPTALDH1A1PKM | |
| SCHEMBL19981418 | 0.80 | MAPT (0.64) | SMN1; SMN2HPGDMAPTALDH1A1PKM | |
| SCHEMBL6755340 | 0.73 | MAPT (0.54) | SMN1; SMN2HPGDMAPTALDH1A1RAB9A | |
| SCHEMBL4097866 | 0.71 | SMN1; SMN2 (0.63) | SMN1; SMN2MAPTALDH1A1RAB9AKMT2A | |
| SCHEMBL1691061 | 0.70 | MAPT (0.68) | SMN1; SMN2HPGDMAPTALDH1A1RAB9A | |
| SCHEMBL10816647 | 0.70 | RAB9A (0.71) | SMN1; SMN2HPGDMAPTALDH1A1RAB9A | |
| SCHEMBL19994399 | 0.70 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPTALDH1A1RAB9ALMNA | |
| SCHEMBL19994395 | 0.69 | MAPT (0.66) | SMN1; SMN2HPGDMAPTALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512602-B1 | INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2023-03-07 | — | — | US | disclosed |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2023-03-07 | — | — | US | disclosed |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2021-07-22 | — | — | US | disclosed |
| WO-2018050656-A2 | INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | SMN1; SMN2 4284/4885HPGD 795/4885MAPT 2930/4885 |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | SMN1; SMN2 4284/4885HPGD 795/4885MAPT 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.